An mRNA vaccine, a cousin to the COVID vaccines that blunted the pandemic, has entered human trials as a treatment for lung ...

Prenatal gene therapy via mRNA LNPs fixes faulty genes in fetal brain cells in animal model of neurodevelopmental syndrome.

New research underscores the role of the immune system in depression, linking inflammation to poor response to standard ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Moderna shares rebound after six days of losses. Analysts mixed on stock with Strong Sell rating but potential for future growth.

Anyone who got sick with COVID-19 during the summer wave in South Florida has some protection against a future infection, but ...

A single COVID-19 mRNA vaccine dose provided similar protection to that conferred by a 2-dose series among immunocompetent patients aged 5 years and older.

On Thursday, Moderna Inc (MRNA) stock saw a decline, ending the day at $52.8 which represents a decrease of $-0.59 or -1.11% from the prior close of $53.39. The stock opened at $53.39 and touched a ...

Researchers are exploring a new mRNA delivery technique to treat genetic conditions in the fetal brain, potentially ...

A new study shows that a biomedical tool can successfully deliver genetic material to edit faulty genes in developing fetal brain cells. The technology, tested in mice, might have the potential to ...